Opinion

Video

Final Thoughts

Author(s):

Zahra Mahmoudjafari, PharmD, MBA, BCOP, FHOPA,Amir Ali, PharmD, BCOP

The panel discussion concludes with final thoughts on the future landscape of newly diagnosed multiple myeloma.

Newsletter

Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights.

Subscribe Now!
Related Videos
2 experts are featured in this series.
2 experts are featured in this series.
2 experts are featured in this series.
2 experts are featured in this series.
2 experts are featured in this series.
Hematology -- Image credit: DIgilife | stock.adobe.com
2 experts are featured in this series.
1 expert in this video
1 expert in this video
Related Content
Visualization of plasma cell in multiple myeloma | Image Credit: © ArtificialHorizons - stock.adobe.com
July 8th 2025

Isa-KRd Induction Achieves 95% Response Rate in Multiple Myeloma

Alexandra Gerlach, Associate Editor
The AQUILA Debate: Daratumumab for Treatment of Smoldering Multiple Myeloma
January 31st 2025

The AQUILA Debate: Daratumumab for Treatment of Smoldering Multiple Myeloma

Alexandra Gerlach, Associate Editor
Visualization of CAR T-cell among red blood cells | Image Credit: © Olha - stock.adobe.com
July 1st 2025

Cilta-Cel Spurs Remission Milestone—But Is It a Cure?

Alexandra Gerlach, Associate Editor
Pharmacy Focus: Oncology Edition
April 17th 2023

Pharmacy Focus: Oncology Edition - Consider Treatment Sequences Carefully in Myeloma

Illustration of immunotherapy attacking multiple myeloma cells | Image Credit: © Noel - stock.adobe.com
June 27th 2025

Is Belantamab Mafodotin Making a Comeback?

Alexandra Gerlach, Associate Editor
Multiple myeloma -- Image credit: LASZLO | stock.adobe.com
June 25th 2025

Continuous Subcutaneous Lenalidomide Shows Promise in Reducing Toxicity in R/R Multiple Myeloma

Alana Hippensteele, Lead Editor